SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the “Company”), comments on the new COVID Vaccine policy adopted by the US FDA. The new FDA COVID Vaccine Booster Shots policy [1] is based on the findings that the groups that benefit from repeat

The Food and Drug Administration will no longer approve COVID-19 vaccines for healthy people under 65 without rigorous trials.

Advisers to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of recommending that COVID-19 vaccines for 2025-26 should target newer strains of the JN.1 variant.

Healthy and under the age of 65? You might not need to receive an annual COVID-19 booster. What to know about new guidelines.

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

As the Trump administration’s FDA moves to limit approval for COVID-19 booster shots, millions of Americans under 65 may find themselves without access this fall. However, until Friday, there’s still time to influence this decision, pro or con, through the FDA’s public comment portal.

Moderna filed for FDA approval of its mRNA-1083 combination shot last year. The submission put the biotech on track to win approval in adults aged 50 and older in November 2025. However, at the start of May, Moderna pushed back the expected approval date to 2026 after the FDA asked to see phase 3 efficacy before making a decision on authorization.

President Donald Trump’s administration is slated to lay out its approach to Covid vaccination at an event Tuesday that could spell major changes in what is required to get regulatory approval for immunizations.